Ansamycin antibiotic compound that inhibits Hsp90 activity (IC50 = 2 μM) by binding to the ATP-binding site. Exhibits antitumor and cytocidal activities (IC50 ~ 0.4 μM) by causing degradation of key oncogenic client proteins such as ErbB2 and cRaf1. Displays higher affinity and potency than geldanamycin (Cat. No. 1368).
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble in DMSO|
Preparing Stock Solutions
The following data is based on the product molecular weight 558.67. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.79 mL||8.95 mL||17.9 mL|
|5 mM||0.36 mL||1.79 mL||3.58 mL|
|10 mM||0.18 mL||0.89 mL||1.79 mL|
|50 mM||0.04 mL||0.18 mL||0.36 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Ono et al (1982) Antitumor and cytocidal activities of a newly isolated benzenoid ansamycin, macbecin I. Gann. 73 938 PMID: 6186564
Uehara et al (2003) Natural product origins of Hsp90 inhibitors. Curr.Cancer Drug Targets 3 325 PMID: 14529384
Martin et al (2008) Molecular characterization of macbecin as an Hsp90 inhibitor. J.Med.Chem. 51 2853 PMID: 18357975
If you know of a relevant reference for Macbecin I, please let us know.
View Related Products by Product Action
Keywords: Hsp90 inhibitors inhibits Heat Shock Protein 90 MacbecinI antibiotics Hsp90
Citations for Macbecin I
Citations are publications that use Tocris products.
Currently there are no citations for Macbecin I. Do you know of a great paper that uses Macbecin I from Tocris? If so please let us know.
Literature in this Area
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.